Tender detail
Non-exclusive rebate agreements for ranibizumab medicines under an open-house model
Summary
The procurement concerns non-exclusive rebate agreements for medicines containing ranibizumab as a 10 mg/ml injection solution in a vial (ATC code S01LA04). Agreements are concluded through an open-house model, with no supply exclusivity; quantities are unknown and no minimum purchase volume is guaranteed. The agreements end no later than 31 December 2027.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.